Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports

Addict Behav. 2014 Mar;39(3):562-5. doi: 10.1016/j.addbeh.2013.11.005. Epub 2013 Nov 10.

Abstract

Objective: It is commonly accepted that pathological gambling results from the interaction of multiple risk factors. Among these, dopamine replacement therapy (DRT) prescribed for Parkinson disease can be cited. Another dopamine agonist, aripiprazole, could be a new risk factor. We decided to explore this potential adverse drug reaction (ADR).

Method: Based on a cohort of 166 pathological gamblers starting treatment in our department, data of each of the 8 patients treated by aripiprazole at inclusion were analyzed.

Results: The patients involved were schizophrenic or bipolar, mostly young men with a history of addictive disorders and regular gambling prior to the prescription of aripiprazole. For each one of them, the causality of aripiprazole was considered, using an algorithm. The probability that pathological gambling is actually due to aripiprazole is "possible" in 7 cases out of 8, and "doubtful" in one.

Conclusions: Adverse drug reactions were confronted with other already published case reports. Dopamine partial agonist mechanism of aripiprazole could explain the occurrence of pathological gambling.

Keywords: Adverse drug reaction; Aripiprazole; Causality; Dopamine partial agonist; Pathological gambling.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antipsychotic Agents / therapeutic use*
  • Aripiprazole
  • Bipolar Disorder / complications
  • Bipolar Disorder / drug therapy*
  • Dopamine Agonists / therapeutic use*
  • Female
  • Gambling* / complications
  • Humans
  • Male
  • Middle Aged
  • Piperazines / therapeutic use*
  • Quinolones / therapeutic use*
  • Risk Factors
  • Schizophrenia / complications
  • Schizophrenia / drug therapy*
  • Young Adult

Substances

  • Antipsychotic Agents
  • Dopamine Agonists
  • Piperazines
  • Quinolones
  • Aripiprazole